Telix Posts 11% Q1 Revenue Growth to US$230M and Advances Phase 3 ProstACT Trial
Telix reported Q1 2026 group revenue of US$230 million, up 11% sequentially and 24% year-over-year, with Precision Medicine revenue rising to US$186 million (+16% QoQ). The company reaffirmed FY 2026 guidance at US$950-970 million and advanced its Therapeutics pipeline, completing Phase 3 ProstACT Part 1 safety objectives and resubmitting the TLX101-Px NDA.
1. Q1 Financial Performance
Telix’s Q1 2026 unaudited group revenue reached US$230 million, a 24% increase year-over-year and 11% rise sequentially, with third-party TMS contributions holding at US$44 million. The company reaffirmed its FY 2026 revenue guidance range of US$950 to US$970 million.
2. Precision Medicine Segment Growth
Precision Medicine revenue climbed to US$186 million, up 23% year-over-year and 16% quarter-over-quarter, driven by strong dose volume growth for Illuccix and Gozellix in the U.S. This performance reflects market share gains through disciplined sales execution, pricing strategies and scalable pharmacy distribution.
3. Therapeutics Pipeline Milestones
In its Therapeutics unit, Telix achieved key milestones: its ProstACT Phase 3 Part 1 trial met safety and dosimetry objectives with no new safety signals and no adverse drug interactions, and engagement has begun with regulators for Part 2 enrollment. The company also resubmitted the NDA for TLX101-Px in the U.S., filed an MAA for Pixlumi® in Europe and received NMPA acceptance for TLX591-Px in China.